World Health Organization Sounds Warning Over Critical Lack of Weight-Loss Injections
Under one in 10 people eligible to benefit from obesity jabs such as Wegovy can access them, warns the WHO as it issues its inaugural advice on the therapies.
Considering more than one billion individuals worldwide currently obese, it is urging increased and just availability to this class of drugs.
Per forecasts, more than two billion could be obese by 2030 without intervention.
"The latest guidelines affirms that excess weight is a chronic disease that can be addressed with comprehensive and continuous treatment," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are significant hurdles to broad availability to the injections that can aid individuals in losing substantial weight, notes the organization.
Skinny Jab Supply Crisis
Despite the present most favorable outlook, the supply of GLP-1 therapies would only suffice for about 100 million people – less than 10% of the global need, per the WHO.
The advice calls on governments and firms to expand access, via measures such as licensing agreements.
Exclusive production rights on a key compound – the main component of a leading brand – is scheduled to end in multiple countries in 2026.
How Obesity Drugs Operate
These medications mimick a natural hormone to delay gastric emptying, reduce hunger and enhance feelings of fullness so people consume fewer calories.
Individuals commonly start to lose weight within a few weeks of commencing the once-weekly jabs.
Research points to users may put most of the weight back on after a year of discontinuing the drug, because their typical hunger return.
Being overweight or obese raises your chance for experiencing medical conditions, such as type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight impacts people in countries worldwide and was responsible for over three and a half million deaths worldwide in 2024, as per the WHO.